CCL5 and cancer: However, we found that CCL5-activated CCR1 preferentially recruited Gαi, which rarely affects the ERK kinase pathway (Fig. 6C and D), and that it inhibited STAT3 phosphorylation by upregulating ITPR3, which is essential for both immune activation and cancer pathogenesis.